Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Psychophysiology. 2015 Sep 24;52(12):1632–1645. doi: 10.1111/psyp.12548

Figure 5.

Figure 5

Grand average waveforms for controls at age 17 who either remained controls or developed EXT by age 29. Grand average waveforms associated with target trials measured during intake (age 17) assessment are presented. The two waveforms coincide with participants identified as controls at age 17 who either eventually met diagnosis for any EXT disorder, or, remained free of any EXT disorder approximately twelve years later.